

## **CURRICULUM VITAE**

**Dr. David Hawkins**

**CEO**

**The Higher Learning Company**

### **OFFICE ADDRESS**

2121 Fothergill Drive  
Evans, GA 30809  
912-398-6577

### **PLACE OF BIRTH**

Jacksonville, Florida

### **EDUCATION**

University of Georgia  
Athens, Georgia  
1971, B.S. Pharmacy

University of Michigan  
Ann Arbor, Michigan  
1974, PharmD

### **Residency:**

University Hospital  
The University of Michigan Medical Center  
Ann Arbor, Michigan  
September 1972 - July 1974  
Chief Resident July 1, 1973-June 30, 1974

### **Additional Education:**

Sixteenth Graduate Summer Session in Epidemiology  
University of Minnesota  
June 21 - July 11, 1981

Clinical Epidemiology and Biostatistics  
McMaster University  
Hamilton, Ontario  
July 1 - December 31, 1982

Measurement, Design, and Analysis Methods  
For Health Outcomes Research  
Harvard School of Public Health  
June 16 – 19, 1998

## **ACADEMIC APPOINTMENTS:**

July 1, 2012 – July 2015: Vice President for Academic Affairs and Dean of Pharmacy, California Health Sciences University, Fresno, California.

June 1, 2007 – June 30, 2012: Professor and Dean, California Northstate College of Pharmacy, Sacramento, California.

October 17, 2006 – June 1, 2007: Director, South University Quality Enhancement Plan.

January 1, 2005 – June 1, 2007: Professor of Pharmacy Practice, South University School of Pharmacy, Savannah, Georgia.

June 1, 2005 – February 16, 2007: Senior Associate Dean, South University School of Pharmacy, Savannah, Georgia.

January 1, 2005 – September 1, 2006: Chair of Pharmacy Practice, South University School of Pharmacy, Savannah, Georgia

August 21, 2001 – December 31, 2004: Senior Associate Dean and Professor, Mercer University Southern School of Pharmacy, Atlanta, Georgia

July 1, 2000- June 1, 2002: Interim Director of the Center for Health Outcomes Research, Mercer University

November 1, 1999 – June 1, 2002: Member, Center for Health Outcomes Research, Mercer University

December 14, 2000 – August 20, 2001: Acting Associate Dean for Health and Administrative Services, Mercer University Southern School of Pharmacy, Atlanta, Georgia

September 1, 1999 – August 20, 2001: Professor and Chair of Pharmacy Practice, Mercer University Southern School of Pharmacy, Atlanta, Georgia

April 1, 1987 – July 1, 2003: Clinical Professor of Medicine, Medical College of Georgia School of Medicine, Augusta, Georgia.

April 1, 1987 – August 31, 1999: Assistant Dean for Clinical Pharmacy, Medical College of Georgia School of Medicine, Augusta, Georgia

September 1, 1991 – August 31, 1999: Professor of Pharmacy, University of Georgia College of Pharmacy, Athens, Georgia.

April 1, 1987 – April 1, 1998: Assistant Dean of Pharmacy, University of Georgia College of Pharmacy, Athens, Georgia.

April 1, 1987 - June 30, 1991: Associate Professor of Pharmacy, University of Georgia College of Pharmacy, Athens, Georgia.

March 1, 1984 - March 31, 1987: Associate Professor of Family Medicine and Head Clinical Pharmacy Section, East Carolina University School of Medicine, Greenville, North Carolina.

March 1, 1984 - March 31, 1987: Clinical Associate Professor of Pharmacy, University of North Carolina at Chapel Hill School of Pharmacy, Chapel Hill, North Carolina.

September 1, 1980 - February 29, 1984: Associate Professor of Pharmacy, University of Texas at Austin, and Associate Professor of Family Practice and Pharmacology, University of Texas Health Science Center at San Antonio, Texas.

August 1, 1980 - February 29, 1984: Research Coordinator for Department of Family Practice, University of Texas Health Science Center at San Antonio, Texas.

September 1, 1977 - August 31, 1980: Assistant Professor of Family Practice and Pharmacology, University of Texas Health Science Center at San Antonio, Texas.

September 1, 1974 - August 31, 1980: Assistant Professor of Pharmacy, College of Pharmacy, University of Texas at Austin.

September 1, 1975 - August 31, 1977: Instructor of Family Practice and Pharmacology, University of Texas Health Science Center at San Antonio, Texas.

### **PROFESSIONAL AND HOSPITAL APPOINTMENTS:**

July 2000 – December 31, 2004: Pharmacy Advisory Board, Grady Health System, Atlanta, GA.

January 1995 –August 1999: Co-Director, Center for Clinical Investigation, Medical College of Georgia.

January 1990 – August 1999: Delegate for the Medical College of Georgia to the United States Pharmacopeial Convention.

January 1990 - December 1992: Liaison representative for the Medical College of Georgia to the University Hospital Consortium Technology Advancement Center.

July 1989 - July 1990: Member, Human Assurance Committee, the Medical College of Georgia.

June 1989: Member, American Society of Hospital Pharmacists Committee for Drafting ASHP Guidelines: Standard for Ambulatory Care Pharmacy Services.

July 1988: American Association and Colleges of Pharmacy Section of Teachers of Clinical Instruction Planning Commission.

July 1, 1986 - March 31, 1987: Member, University Policy Committee on Human Research, East Carolina University, Greenville, North Carolina.

October 1980 - February 29, 1984: Member, Institutional Review Board, Chairman 1983, The University of Texas Health Science Center at San Antonio, Texas.

April 1978 - December 1980: Member, American Association of Colleges of Pharmacy - American Society of Hospital Pharmacists Joint Committee, Chairman, 1979 - 1980.

April 1977 - April 1978: Member, Council on Education and Manpower, American Society of Hospital Pharmacists.

July 1977 - June 1978: Board of Directors, Bexar County Pharmaceutical Association, San Antonio, Texas.

September 1, 1975 - February 29, 1984: Associate Member, Medical-Dental Staff, Bexar County Hospital District, San Antonio, Texas.

July 1977 - June 1980: Consulting Member, Pharmacy and Therapeutics Committee, Bexar County Hospital District, San Antonio, Texas.

July 1973 - June 1974: Chief Resident in Clinical Pharmacy, University of Michigan Medical Center, Ann Arbor, Michigan.

June 1971 - June 1972: Intern in Hospital Pharmacy, Tallahassee Memorial Hospital, Tallahassee, Florida.

**EDITORIAL BOARDS:**

Clinical Pharmacy (1982 - 89)

Family Practice Research Journal (1980 - 85)

Clinical and Applied Thrombosis/Hemostasis (1995 - 2001)

Orthopedics DocZine, (2003-2005)

**NATIONAL SPEAKERS BUREAUS:**

Aventis (Cardiovascular Therapeutics)

Bristol-Myers Squibb Company (Lipid Disorders and Diabetes Mellitus)

Pfizer (Lipid Disorders)

Astra-Zeneca (Anticoagulant Therapy and Lipid Disorders)

Sankyo Pharma (Hypertension and Lipid Disorders)

Sanofi Synthelabo (Cardiovascular Therapeutics)

**INVITED LECTURES AND PRESENTATIONS:**

1. "Utilization of Subprofessional Personnel," Regional North Florida - South Georgia Hospital Pharmacy Seminar, Tallahassee, Florida, February 10, 1972.
2. "Preparation, Storage, and Use of Skin Bank Fluid in a Community Hospital," ASHP Midyear Clinical Meeting, Las Vegas, Nevada, December 1972.
3. "A Comparison of Crystalloid Versus Colloid Solutions in the Resuscitation of the Burned Patient: A Retrospective Study," University of Michigan, PharmD. Seminar, March 1973.
4. "Special Dosing of Drugs in Patients with Impaired Renal Function," University of Michigan Burn Surgeons' Seminar, Ann Arbor, Michigan, August 1973.
5. "Updating the Pharmaceutical Consultant: The Role of the Pharmacist in Long-Term Patient Care," Austin, Texas, October 9-10, 1974.
6. "Objectives, Methods and Materials for Teaching Rational Antihypertensive Therapy," Fourth Annual American College of Clinical Pharmacology Meeting, Atlantic City, New Jersey, May 2, 1975.
7. "Family Practice and the Pharmacist," Schering Hospital Pharmacy Seminar, Dallas, Texas, May 10, 1975.
8. "Monitoring Drug Therapy in the Long-Term Care Patient," Annual Midyear, American College of Apothecaries, Dallas, Texas, May 18, 1975.
9. "The Rational Treatment of Urinary Tract Infections," Family Practice Grand Rounds, The University of Texas Health Science Center, San Antonio, Texas, July 1, 1975.

10. "The Pharmacist's Involvement in a Hypertension Clinic," Central Texas Society of Hospital Pharmacists Meeting, San Antonio, Texas, July 15, 1975.
11. "The Management of a Complicated Seizure Disorder: A Therapeutic Dilemma," American Society of Hospital Pharmacists Midyear Clinical Meeting, Washington, D.C., December 1975.
12. "The Technical Foundation of Professional Prerogative," American Pharmaceutical Association Meeting, New Orleans, Louisiana, April 3, 1976.
13. "Hypermetabolism of Diphenylhydantoin: A Pharmacokinetic Study," American Academy of Neurology Annual Meeting, Toronto, Canada, April 29, 1976.
14. "The Management of the Diabetic Patient," Texas Pharmaceutical Association Annual Seminar, Austin, Texas, September 11, 1976.
15. "A Primary Care Clinical Laboratory for Pharmacy Research and Training," American Society of Hospital Pharmacists Midyear Clinical Meeting, Anaheim, California, December 8, 1976.
16. "Therapeutic Management of Diabetes: Diet, Insulin and Oral Hypoglycemics," AHEC Seminar, Laredo, Texas, December 12, 1976.
17. "The Rational Use of Oral Hypoglycemic Agents," Family Practice Grand Rounds, The University of Texas Health Science Center at San Antonio, San Antonio, Texas, January 22, 1977.
18. "Mechanisms of Drug Interactions," McAllen General Hospital Medical Staff Conference, McAllen, Texas, July 22, 1977.
19. "Integration of Contemporary Pharmacy Practice and Innovative Services in Ambulatory Care," Association of Military Surgeons Annual Meeting, San Antonio, Texas, November 2, 1976.
20. "The Rational Basis for Over-the-Counter Self-Medication," The University of Texas Regional Pharmacy Seminar, San Antonio, Texas, November 2, 1977.
21. "The Clinical Practice of Pharmacy in an Ambulatory Care Center," North Central Texas Society of Hospital Pharmacists Fall Seminar, Ft. Worth, Texas, November 6, 1977.
22. "Characterization of Patient-Specific Michaelis-Menten Constants for Individualization of Phenytoin Therapy," American Society of Hospital Pharmacists 12th Midyear Clinical Meeting, Atlanta, Georgia, December 6, 1977.
23. -
24. "The Newer Anti-Inflammatory Drugs - An Update," Family Practice Grand Rounds, The University of Texas Health Science Center at San Antonio, San Antonio, Texas, February 1, 1978.
25. "Ambulatory Care Clinical Pharmacy Programs," Tufts-New England Medical Center, Boston, Massachusetts, March 10, 1978.
26. "Ambulatory Care Clinical Pharmacy Service, Research and Education," Conference on Role Definition of Clinical Pharmacy, Denver, Colorado, April 6, 1978.
27. "The Impact of Clinical Pharmacy Services on Primary Health Care," U.S. Air Force Annual Pharmacy Seminar, San Antonio, Texas, May 4, 1978.
28. "Effective Communication with the Ambulatory Patient," American Society of Hospital Pharmacists Institute on Ambulatory Pharmacy Service, Memphis, Tennessee, June 14, 1978.
29. "A Randomized Controlled Trial of the Clinical Pharmacist in Primary Care," Oregon State University

School of Pharmacy, Corvallis, Oregon, March 29, 1979.

30. "Establishing a Therapeutic Relationship with the Geriatric Patient," Kaiser Pharmaceutical Association Continuing Education Meeting, Portland, Oregon, March 29, 1979.
31. "Effectiveness of Pharmacists Managing Hypertensive Patients," American Society of Hospital Pharmacists Midyear Clinical Meeting, Las Vegas, Nevada, December 5, 1979.
32. "What Constitutes Clinical Pharmacy Education and Research?" The University of South Carolina College of Pharmacy, Columbia, South Carolina, January 17, 1980.
33. "Ambulatory Patient Care: The Role of the Clinical Pharmacist," American College of Clinical Pharmacology 9th Annual Meeting, Washington, D.C.,
34. May 15, 1980.
35. "The Important Elements in Patient Communication and Patient Compliance," Georgia Society of Hospital Pharmacists Annual Seminar, Athens, Georgia, October 1, 1978.
36. "The Clinical Functions of a Pharmacist in Ambulatory Patient Care," North Louisiana Society of Hospital Pharmacists Meeting, Monroe, Louisiana, November 20, 1980.
37. "The Clinical Pharmacology of Oral Antidiabetic Medications," Family Practice Grand Rounds, The University of Texas Health Science Center, San Antonio, Texas, May 6, 1981.
38. "Pharmacologic Management of Type 2 Diabetes Mellitus," Bexar County Pharmaceutical Association Seminar on Diabetes Mellitus, San Antonio, Texas, May 17, 1981.
39. "Drugs in Pregnancy," Southern Medical Association Meeting, New Orleans, Louisiana, November 16, 1981.
40. "Role of Second Generation Oral Hypoglycemic Agents," American Society of Hospital Pharmacists Midyear Clinical Meeting, New Orleans, Louisiana, December 9, 1981.
41. "Research Architecture: Advantages and Disadvantages of Various Experimental Designs," The American Academy of Family Physicians Regional Research Workshop, San Antonio, Texas, May 14, 1982.
42. "Anticoagulation Clinic Care Versus Routine Clinic Care in the Management of Patients on Warfarin Sodium - a Research Proposal," American Society of Hospital Pharmacists Midyear Clinical Meeting, Los Angeles, California, December 5, 1982.
43. "When Should Mild Hypertension be Treated?" American College of Clinical Pharmacy Southwest Regional Continuing Education Conference, San Antonio, Texas, April 15, 1983.
44. "Hypertension Treatment: When Rather Than How," Texas Society of Hospital Pharmacists Annual Meeting, San Antonio, Texas, March 1, 1984.
45. "Analysis of Methods Employed in Identifying and Recruiting Study Subjects," North American Primary Care Research Group Annual Meeting, Orlando, Florida, May 2, 1984.
46. "Diabetes Mellitus: The Oral Agents," The American Society of Hospital Pharmacists Midyear Clinical Meeting, Dallas, Texas, December 14, 1984.
47. "Treatment of Deep Vein Thrombosis," Southeastern Regional Symposium on Deep Vein Thrombosis, Atlanta, Georgia, April 9, 1985.
48. "COPING: Coumadin Patient Information Guide - A Computerized Program for Managing an

Anticoagulation Clinic," The American Society of Hospital Pharmacists Midyear Clinical Meeting, New Orleans, Louisiana, December 9, 1985.

49. "Establishing Safe and Effective Anticoagulation Therapy," Atlanta Academy of Institutional Pharmacists, Atlanta, Georgia, March 13, 1986.
50. "The Pharmacologic Management of Essential Hypertension," Tidewater Pharmaceutical Association, Norfolk, Virginia, March 23, 1986.
51. "The Content of Clinical Pharmacy Research, Service, and Education," The University of Georgia College of Pharmacy, Athens, Georgia, August 1, 1986.
52. "Clinical Research - A Roundtable Discussion," American Society of Hospital Pharmacists Midyear Clinical Meeting, Las Vegas, Nevada, December 9, 1986.
53. "Effectiveness of Diuretic Plus Betablocker vs. High Dose Diuretic Therapy in the Management of Black, Adult Hypertensives," The Second International Interdisciplinary Conference on Hypertension in Blacks, Atlanta, Georgia, March 6, 1987.
54. "Selecting the Right Antibiotic," Family Practice Update, East Carolina University School of Medicine, Greenville, North Carolina, March 11, 1987.
55. "Hypertension in Special Populations: Management Problems," Georgia Community Health Statewide Conference, Savannah, Georgia, September 28, 1987.
56. "Clinical Research and Medical Teaching: A Roundtable Discussion," American Society of Hospital Pharmacists Midyear Clinical Meeting, Atlanta, Georgia, December 8, 1987.
57. "Clinical Pharmacology of the Nonsalicylate Nonsteroidal Anti-inflammatory Drugs," American Pharmaceutical Association Annual Meeting, Atlanta, Georgia, March 15, 1988.
58. "Metabolic Effects of Antihypertensive Agents," Issues Affecting Pharmacy: Cost Effectiveness Symposium, Aurora, Colorado, September 16, 1988.
59. "The Differential Treatment of Essential Hypertension," Wake AHEC Continuing Education Meeting, Raleigh, North Carolina, October 27, 1988.
60. "Pharmacotherapy of Primary Hypertension," Postgraduate Seminar on Coronary Care, Jekyll Island, Georgia, October 30, 1988.
61. "Primary Care Research and Clinical Trial Methodologies," American Society of Hospital Pharmacists Midyear Clinical Meeting, Dallas, Texas, December 8, 1988.
62. "Metabolic Effects of Antihypertensive Agents," Southeast Regional Symposium: Issues Affecting Pharmacy, Tarpon Springs, Florida, May 12, 1989.
63. "Analysis of the Drug Information Resources of Medical Students, Physicians' Assistants, and Physicians," American Society of Hospital Pharmacists Midyear Clinical Meeting, Atlanta, Georgia, December 6, 1989.
64. "Drug Use in the Elderly", An Internal Medicine Symposium on The Special Needs of An Aging Population, Callaway Gardens, Pine Mountain, Georgia, October 13, 1990.
65. "Therapeutic Approaches in The Treatment of Hypertension", A Symposium on Cost Effective Cardiovascular Therapy, Scottsdale, Arizona, November 18, 1990.
66. "Rational Principles of Anticoagulant Therapy", Continuing Education Conference for Nurses and

Pharmacists, Yakima, Washington, November 27, 1990.

67. "The Pathophysiology and Treatment of Gout and Hyperuricemia", VA Hospital Pharmacy Seminar, Augusta, Georgia, January 17, 1991.
68. "The Effectiveness of Clinical Pharmacy Interventions", Internal Medicine Grand Rounds, Eisenhower Army Medical Center, Fort Gordon, Georgia, March 29, 1991.
69. "The Diabetic Hypertensive", 43rd Annual Postgraduate Pharmacy Seminar, The University of Georgia, Athens, Georgia, April 21, 1991.
70. "The Pathophysiologic and Treatment Interactions Between Hypertension and Atherosclerosis", American College of Clinical Pharmacy Annual Meeting, Toronto, Canada, August 8, 1992.
71. "Drug Delivery Systems", Therapeutic and Cost-Effectiveness Issues in Hypertension Symposium, American Society of Hospital Pharmacists Midyear Clinical Meeting, Orlando, Florida, December 9, 1992.
72. "Economic Evaluation of Alternative Strategies for Preventing Thromboembolism in Total Hip Replacement", American College of Clinical Pharmacy (Satellite Symposium), Ft. Lauderdale, Florida, February 7, 1993.
73. "Differentiating Drug Delivery Systems of Cardiovascular Agents", Drug Delivery Systems in Cardiovascular Medicine Symposium, Anaheim, California, March 18, 1993.
74. "Clinical Update on Antithrombotic Therapy," Florida Society of Hospital Pharmacists Midyear Meeting, Ft. Lauderdale, Florida, April 17, 1993.
75. "Novel Drug Delivery Systems for Cardiovascular Agents," VA Hospital Pharmacy Regional Meeting, Albany, New York, May 7, 1993.
76. "The Diagnosis and Management of Lipid Disorders", Georgia Pharmaceutical Association Annual Meeting, Asheville, North Carolina, June 13, 1993.
77. "Contemporary Therapy of Hypertension: New Recommendations in the Fifth Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure," University of Missouri-Kansas City School of Pharmacy Continuing Education Program, Kansas City, Missouri, June 27, 1993.
78. "Therapy for Dyslipidemia: Choosing the Appropriate Regimen for the Patient with Coronary Disease," American College of Clinical Pharmacy Annual Meeting (Satellite Symposium), Reno, Nevada, August 15, 1993.
79. "New Hypertension Guidelines: JNC-V," American College of Clinical Pharmacy Annual Meeting, Reno, Nevada, August 17, 1993.
80. "Diabetes Update: Management," Florida Society of Hospital Pharmacists Annual Meeting, Orlando, Florida, August 21, 1993.
81. "Guidelines for Treating Hypertension: JNCV", Chesapeake College of Clinical Pharmacy Fall Symposium, Columbia, Maryland, September 24, 1993.
82. "Secondary Prevention in Patients with Lipid Disorders", Southeast Regional Pharmacy Cholesterol Council Meeting, Charleston, South Carolina, October 2, 1993.
83. "The Pathophysiology and Treatment of Deep Vein Thrombosis", Southwest Florida Society of Hospital Pharmacists Meeting, Tampa, Florida, October 23, 1993.



84. "Prevention of Deep Vein Thrombosis in Patients Undergoing Total Hip Replacement", Southeast Florida Society of Hospital Pharmacists Meeting, Ft. Lauderdale, Florida, November 1, 1993.
85. "Deep Vein Thrombosis: A Focus on Enoxaparin", Oakbrook, Illinois, December 2, 1993.
86. "An Economic Evaluation of Enoxaparin in DVT Prophylaxis", American Society of Hospital Pharmacists Midyear Clinical Meeting Symposium, Atlanta, Georgia, December 5, 1993.
87. "JNC-V: A Step Forward or a Step Backward?" American Society of Hospital Pharmacists Midyear Clinical Meeting, Atlanta, Georgia, December 6, 1993.
88. "Cost-effectiveness of DVT Prophylaxis Following Hip Replacement Surgery". The Changing Role of the Hospital Pharmacist Meeting, New York, New York, January 18, 1994.
89. "Dyslipidemia and Coronary Disease: The Rationale and Effectiveness of Secondary Prevention", Society of Air Force Pharmacists Meeting, Vandenberg, California, January 21, 1994.
90. "The Future of Pharmacy Practice: The Role of an Academic Pharmacy Practice Department," University of Florida College of Pharmacy, Gainesville, Florida, February 17, 1994.
91. "DVT Prophylaxis: Efficacy and Cost-Effectiveness," Central Illinois Society of Hospital Pharmacists Meeting, Rockford, Illinois, March 23, 1994.
92. "Cost-Effectiveness of DVT Prophylaxis Following Major Orthopedic Surgery," Pharmacy Grand Rounds, Johns Hopkins University Medical Center, Baltimore, Maryland, April 13, 1994.
93. "Update on the Treatment of Hypercholesterolemia," The University of Georgia College of Pharmacy 46th Annual Postgraduate Seminar, Athens, Georgia, April 17, 1994.
94. "Clinical Outcomes and Cost-Effectiveness," New Jersey Society of Hospital Pharmacists Annual Meeting, Long Branch, New Jersey, May 21, 1994.
95. "The Prevention of Deep Vein Thrombosis After Total Hip Replacement Surgery," Wyoming Pharmaceutical Association Annual Meeting, Gillette, Wyoming, June 17, 1994.
96. "Practical Pharmacoeconomics: Introduction to Concepts," Nebraska Society of Hospital Pharmacists Fall Meeting, Omaha, Nebraska, September 30, 1994.
97. "Cost-Effectiveness of Low Molecular Weight Heparins," Pharmacy Grand Rounds, Grady Memorial Hospital, Atlanta, Georgia, October 4, 1994.
98. "The Efficacy and Cost-Effectiveness of DVT Prophylaxis in Hip and Knee Surgery," Pharmacy Grand Rounds, Brigham and Women's Hospital, Boston, Massachusetts, October 6, 1994.
99. "Comparative Pharmacology and Cost-Effectiveness of Anti-Thrombotic Agents," California Society of Hospital Pharmacists Pre-meeting Symposium, San Diego, California, October 13, 1994.
100. "Clinical Pharmacology and Cost-Effectiveness of Low Molecular Weight Heparins," Northern Ohio Pharmaceutical Association Continuing Education Meeting, Cleveland, Ohio, October 19, 1994.
101. "Cost-Effectiveness of Low Molecular Weight Heparin Use," American Society of Hospital Pharmacist. Midyear Clinical Meeting, Miami, Florida, December 6, 1994.
102. "Steps to Take When Your Patient's Antihypertensive Drug Regimen Doesn't Work," American Society of Hospital Pharmacists Midyear Clinical Meeting, Miami, Florida, December 7, 1994.

103. "Low Molecular Weight Heparins versus Unfractionated Heparins: A Comparison of Clinical and Financial Outcomes," Symposium on Multidisciplinary Approach to the Optimal Management of Deep Vein Thrombosis, Dallas, Texas, April 12, 1995.
104. "The Pharmacology and Pharmacoeconomics of the Low Molecular Weight Heparins," American Society of Consultant Pharmacists, San Diego, California, May 21, 1995.
105. "Clinical and Economic Outcomes of Antithrombotic Prophylaxis," American College of Clinical Pharmacy Annual Meeting, Washington, DC, August 8, 1995.
106. "Is Credentialing Necessary to Assure Quality Prescribing?" American College of Clinical Pharmacy Annual Meeting, Washington, DC, August 9, 1995.
107. "An Economic Assessment of Enoxaparin versus Heparin in the Prevention of DVT After Total Hip Replacement," International Society of Haematology Meeting, Istanbul, Turkey, September 7, 1995.
108. "Anticoagulant Therapy: Low Molecular Weight Heparins," Florida Hospital Pharmacy Continuing Education Conference, Orlando, Florida, October 4, 1995.
109. "Principles of Bedside Pharmacy: The Robert G Leonard Memorial Lecture," Corpus Christi, Texas, April 14, 1996.
110. "Risk, Methods, and Justification of DVT Prophylaxis in the Orthopedic Population," National Association of Orthopedic Nurses Congress, Dallas, Texas, June 1, 1996.
111. "Choosing Appropriate Prophylaxis Against Venous Thromboembolic Disease: The Search for Cost-effectiveness," Individual Case Management Association Meeting, Orlando, Florida, September 8, 1996.
112. "Pharmacoeconomics of Low Molecular Weight Heparins," Advances in Anticoagulant, Antithrombotic, and Thrombolytic Drugs International Symposium, Cambridge, Massachusetts, October 21, 1996.
113. "Safety, Efficacy, and Cost-effectiveness of Enoxaparin and Heparin in DVT Prophylaxis," Academy of Managed Care Pharmacy Educational Conference, Orlando, Florida, October 31, 1996.
114. "Comprehensive Calculation of Costs of Clinical Care," ASHP Midyear Clinical Meeting, New Orleans, Louisiana, December 9, 1996.
115. "Anticoagulation," New Mexico Society of Health-Systems Pharmacists Meeting, Mescalero, New Mexico, February 21, 1997.
116. "Helping patients reach the mark: lowering cholesterol to NCEP target levels," Medical Education Systems Regional Symposium, Dallas, Texas, April 19, 1997.
117. "Benefits of lowering cholesterol with statin drugs: results of pivotal trials," Medical Education Systems Regional Symposium. Atlanta, GA, April 26, 1997, San Francisco, California, September 20, 1997.
118. "A vision of pharmacy in the next millennium," The University of Oklahoma College of Pharmacy, Oklahoma City, OK, April 24, 1997.
119. "Arterial Indications for Low Molecular Weight Heparins," Pharmacy Educators Network Conference, Orlando, Florida, June 20, 1997.
120. "Management of Dyslipidemia," Managed Care Conference, Kiawah, South Carolina, September 13, 1997.
121. "Efficacy of low molecular weight heparins for the prevention and treatment of venous thromboembolism," American College of Clinical Pharmacy Annual Meeting, Phoenix, Arizona,

November 9, 1997.

122. "Doctoral clerkship students and pharmaceutical care: a three-year analysis," American College of Clinical Pharmacy 1997 Annual Meeting, Phoenix, Arizona, November 1997.
123. "Analysis of pharmaceutical care activities provided by doctor of pharmacy clerkship students in an acute care setting," 32nd Annual American Association of health-system pharmacist mid-year clinical meeting, Atlanta, Georgia, December 1997.
124. "Low molecular weight heparins: past to future," Pharmacy Educators Network Conference, Orlando, Florida, January 9, 1998.
125. "Managing hypertension in patients with diabetes," American Pharmaceutical Association Annual Meeting, Miami, Florida, March 21, 1998.
126. "A comparison of the statins: implications for drug selection," American Society of Health-System Pharmacists Annual Meeting, Baltimore, Maryland, June 1, 1998.
127. "Treating-to-target: Lessons from recent clinical trials," Louisiana Pharmacists Association Annual Meeting, New Orleans, Louisiana, July 25, 1998.
128. "The critical role of the pharmacist in dyslipidemia management," Louisiana Pharmacists Association Annual Meeting, New Orleans, Louisiana, July 25, 1998.
129. "Clinical use of statins: Is one agent better than another?" Lipid Task Force Annual Conference, Portland, Oregon, September 25, 1998.
130. "Managing hypertension in patients with diabetes", Annual Carolina Seminar, Greensboro, North Carolina, October 7, 1998.
131. "Cost-effectiveness of LMWHs for the outpatient treatment of DVT", American Society of Health-System Pharmacists Midyear Clinical Meeting, Las Vegas, Nevada, December 6, 1998.
132. "Managing hypertension in patients with diabetes", American Society of Health-System Pharmacists Midyear Clinical Meeting, Las Vegas, Nevada, December 8, 1998.
133. "Overview of similarities and differences in statins: a preferred choice in reducing the risk of high cholesterol", American Society of Health-System Pharmacists Midyear Clinical Meeting, Las Vegas, Nevada, December 8, 1998.
134. "Managing hypertension in patients with diabetes to decrease cardiovascular risk", American Pharmaceutical Association Annual Meeting, San Antonio, Texas, March 8, 1999.
135. "Pharmacology and differentiation of low molecular weight heparins", Multidisciplinary Scientific Conference on Issues in Antithrombosis, San Diego, California, June 11, 1999.
136. "Future Roles: Direct Thrombin Inhibitors as Alternatives to Heparins", American College of Clinical Pharmacy Annual Meeting, Los Angeles, California, November 7, 2000.
137. "Venous Thromboembolism: Modulating the Coagulation Cascade", American Society Health-System Pharmacists Midyear Clinical Meeting, Las Vegas, Nevada, December 5, 2000.
138. "Lipid Management: Improving Patient Outcomes and Implementing a Community Pharmacy Lipid Management Program", Alabama Pharmacy Association Meeting, Montgomery, Alabama, February 24, 2001.
139. "Direct Thrombin Inhibitors and Heparin-Induced Thrombocytopenia", State of the Art Antithrombotic

Therapy 2001, Dearborn, Michigan, March 7, 2001.

140. "The Development of Deep Vein Thrombosis", American Pharmaceutical Association 148<sup>th</sup> Annual Meeting, San Francisco, California, March 19, 2001.
141. "Direct Thrombin Inhibitors as Alternatives to Heparins", University of Illinois at Chicago Continuing Education Conference, Oak Brook, Illinois, May 30, 2001.
142. "Duration of Treatment and Extended Treatment of Venous Thromboembolism with Low Molecular Weight Heparins", American Society of Health System Pharmacists Annual Meeting, Los Angeles, California, June 2, 2001.
143. "Lipid Management: Improving Patient Outcomes", Georgia Pharmaceutical Association 126<sup>th</sup> Annual Convention, Ponte Vedra Beach, Florida, June 17, 2001.
144. "Update on the Management of Type 2 Diabetes", Georgia Association of Physician Assistants' 26<sup>th</sup> Annual Conference, Jekyll Island, Georgia, July 21, 2001.
145. "Primary Prophylaxis of Venous Thromboembolism: Current and Emerging Options", Continuing Pharmacy Education Conference, Los Angeles, California, October 13, 2001.
146. "The First Selective Factor Xa Inhibitor, Pentasaccharide (Fondaparinux), Demonstrates a Highly Favorable Pharmacokinetic Profile in Young and Elderly Healthy Subjects", American College of Clinical Pharmacy Annual Meeting, Tampa, Florida, October 22, 2001.
147. "Pentasaccharide (Fondaparinux), the Novel Specific Antithrombotic Agent: In Vitro Protein Binding to Human Plasma and Purified Antithrombin", American College of Clinical Pharmacy Annual Meeting, Tampa, Florida, October 22, 2001.
148. "Pentasaccharide (Fondaparinux), the First Selective Factor Xa Inhibitor, Offers Superior Prevention of Venous Thromboembolic Events After Orthopedic Surgery Compared with Low-Molecular-Weight Heparin", American College of Clinical Pharmacy Annual Meeting, Tampa, Florida, October 23, 2001.
149. "Pentasaccharide superiority over low-molecular-weight heparin for prevention of venous thromboembolism after major orthopaedic surgery is independent of patient age", American Society of Consultant Pharmacists Annual Meeting, Chicago, Illinois, November 9, 2001.
150. "The antithrombotic agent fondaparinux demonstrates a highly favorable pharmacokinetic profile in young and elderly healthy subjects", American Society of Consultant Pharmacists Annual Meeting, Chicago, Illinois, November 9, 2001.
151. "Pentasaccharide, a novel antithrombotic agent: in vitro protein binding to human plasma and purified antithrombin", American Society of Consultant Pharmacists Annual Meeting, Chicago, Illinois, November 9, 2001.
152. "Selective Factor Xa Inhibitors: The Future of VTE Prophylaxis", American Society of Health-System Pharmacists Midyear Clinical Meeting, New Orleans, Louisiana, December 2, 2001.
153. "A New Treatment Paradigm for Type 2 Diabetes", American Society of Health-System Pharmacists Midyear Clinical Meeting, New Orleans, Louisiana, December 3, 2001.
154. "State of the Angiotensin Receptor Blockers (ARB) Class", American Society of Health-System Pharmacists Midyear Clinical Meeting, New Orleans, Louisiana, December 3, 2001.
155. "A New Treatment Paradigm for Type 2 Diabetes", American Pharmaceutical Association Annual Meeting, Philadelphia, Pennsylvania, March 17, 2002.

156. "What's New in Anticoagulation", 2002 Carolina Regional Conference for Senior Care Pharmacists, Charlotte, NC, April 5, 2002.
157. "Hyperlipidemia: New NCEP Guidelines", National Pharmaceutical Association Annual Conference, Houston, Texas, July 23, 2002.
158. "Cost of Thrombosis and Its Complications", American College of Clinical Pharmacy Annual Meeting, Albuquerque, New Mexico, October 21, 2002.
159. "Consistency of Fondaparinux Superiority for Venous Thromboembolism Prevention in Orthopedic Surgery According to Different Composite Efficacy Endpoints", American College of Clinical Pharmacy Annual Meeting, Albuquerque, New Mexico, October 21, 2002.
160. "New Treatment Options for VTE Prevention: The Role of Selective Factor Xa Inhibition", American Society of Consultant Pharmacists Annual Meeting, Anaheim, California, November 16, 2002.
161. "Therapeutic Dilemmas in Antithrombotic Therapy: Fondaparinux versus Enoxaparin – Is There a Clinically Important Difference for VTE Prophylaxis in High-Risk Patients?", 17<sup>th</sup> Annual PICAT Symposium, Atlanta, Georgia, December 7, 2002.
162. "Clinical Trials with Factor Xa Inhibition in the Prevention of Postoperative VTE", American Society of Health-System Pharmacists Midyear Clinical Meeting, Atlanta, Georgia, December 8, 2002.
163. "Role of Duration of Fondaparinux Prophylaxis in Preventing Venous Thromboembolism Following Major Orthopedic Surgery" (with GG Turpie, KA Bauer et al), American Society of Health-System Pharmacists Midyear Clinical Meeting, Atlanta, Georgia, December 11, 2002.
164. "Management of Dyslipidemia in the 21<sup>st</sup> Century: Meeting the Challenge and Optimizing Patient Care", Vanderbilt School of Nursing, Nashville, Tennessee, February 19, 2003.
165. "LMWHs versus Pentasaccharide in the Prevention and Treatment of DVT/PE", Texas Society of Health System Pharmacists, Dallas, Texas, April 4, 2003.
166. "Overview of Anticoagulation Therapies", Pri-Med West Continuing Medical Education Symposium, Long Beach, California, April 5, 2003.
167. "How to Meet the Unmet Need in Patients with Dyslipidemia", American Society of Health-System Pharmacists Annual Meeting, San Diego, California, June 2, 2003.
168. "Update on the Management of Cardiovascular Disease", National Pharmaceutical Association 56<sup>th</sup> Annual Meeting, Las Vegas, Nevada, July 28, 2003.
169. "Is Fondaparinux Cost-Effective in the Prophylaxis of Venous Thromboembolism Following Major Orthopedic Surgery?" The Second International Expert Session on Selective Factor Xa Inhibition, Prague, Czech Republic, September 14, 2003.
170. "Antithrombotic Therapy in the Acute Coronary Syndrome", 2003 Iowa Anticoagulation Symposium, University of Iowa Hospitals and Clinics, Iowa City, Iowa, October 17, 2003.
171. "Fondaparinux versus Enoxaparin for VTE Prophylaxis in High-Risk Patients", 2003 Iowa Anticoagulation Symposium, University of Iowa Hospitals and Clinics, Iowa City, Iowa, October 17, 2003.
172. "Current Management of Dyslipidemia", American College of Clinical Pharmacy Annual Meeting, Atlanta, Georgia, November 2, 2003.
173. "Rationale for Selectively Inhibiting Factor Xa", American College of Clinical Pharmacy Annual

Meeting, Atlanta, Georgia, November 3, 2003.

174. "Pharmaceutical Clinical Technology (PCT): An Outline of Knowledge to Guide Pharmacy Practice, Education, Administration, and Research", American College of Clinical Pharmacy Annual Meeting, Atlanta, Georgia, November 3, 2003.
175. "Peripheral arterial disease: a case study", Pharmacy Invitational Conference on Antithrombotic Therapy, New Orleans, Louisiana, December 6, 2003.
176. "The Optimal INR Intensity for Prevention of Recurrent Venous Thromboembolism", American Society of Health-System Pharmacists Midyear Clinical Meeting, New Orleans, Louisiana, December 8, 2003.
177. "Update in Clinical Trials: Anticoagulation in Venous Thromboembolic Disease", American Society of Health-System Pharmacists Midyear Clinical Meeting, New Orleans, Louisiana, December 9, 2003.
178. "Benign Prostatic Hyperplasia", American Society of Health-System Pharmacists Midyear Clinical Meeting, New Orleans, Louisiana, December 9, 2003.
179. "Cholesterol Management in the Elderly: Cutting Through the Controversy", Managing Common Disease States in the LTC Resident Conference, Coronado, California, March 12, 2004 and Marco Island, Florida, April 23, 2004.
180. "Acute Coronary Syndromes", The University of Georgia College of Pharmacy – Medical College of Georgia School of Medicine Jointly Sponsored Women's Cardiovascular Health Symposium, Augusta, Georgia, March 26, 2004.
181. "Focus on Hypertension Management in Patients with Dyslipidemia", American Pharmaceutical Association Annual Meeting, Seattle, Washington, March 29, 2004.
182. "Focus on Hypertension Management in Patients with Dyslipidemia", Academy of Managed Care Pharmacists Annual Meeting, San Francisco, California, April 1, 2004
183. "Update on Lipid Management Guidelines and Therapy", American Pharmaceutical Association Foundation National Clinical Issues Forum: Metabolic Syndrome, Lake Bluff, Illinois, May 15, 2004.
184. "Evidence for a New Treatment Paradigm for Hypertension and Dyslipidemia", American Academy of Physician Assistants Annual Meeting, Las Vegas, Nevada, June 3, 2004.
185. "Treating Hypertension and Dyslipidemia: Evidence of Synergistic Benefits", American Association of Nurse Practitioners Annual Meeting, New Orleans, Louisiana, June 15, 2004.
186. "Lipid Management Research and Implications for Therapy, National Community Pharmacists Association Annual Meeting, Boston, Massachusetts, October 10, 2004.
187. "New Research, New Approaches to Treatment of Dyslipidemia", Academy of Managed Care Pharmacy 2004 Educational Conference, Baltimore, Maryland, October 13, 2004.
188. "Current National Guidelines: How Evidence Drives Therapy", American Society of Health –System Pharmacists Midyear Clinical Meeting Satellite Symposium on Optimizing Cardiovascular Outcomes in the Management of Dyslipidemia, Orlando, Florida, December 6, 2004.
189. "Targeting Lipid-Lowering Therapy Based on Inflammatory Markers", American Pharmacists Association Annual Meeting, Orlando, Florida, April 4, 2005.
190. "The Treatment of Dyslipidemia: What's New and Why?", Academy of Managed Care Pharmacists Annual Meeting, Denver, Colorado, April 20, 2005.

191. "Update on the Management of Lipid Disorders", APhA Foundation Conference on Metabolic Syndrome, Chicago, Illinois, May 14, 2005.
192. "Targeting Lipid-lowering Therapy: LDL and Beyond", American Society of Health –System Pharmacists Annual Meeting, Boston, Massachusetts, June 13, 2005.
193. "Evidence-based Guidelines for the Prevention and Treatment of Cardiovascular Disease in Women", WalMart Corporate-wide Continuing Education Seminar, Bentonville, Arkansas, February 14, 2006.
194. "The Role of the Pharmacist in Risk Factor Assessment and Management for Coronary Heart Disease", San Diego County Pharmacist Association and Society of Health Systems Pharmacists joint meeting, San Diego, CA, March 16, 2006.
195. "Update on Lipid Management Guidelines and Therapy", APhA Foundation Conference on Metabolic Syndrome, Chicago, Illinois, May 6, 2006.
196. "Comprehensive Lipid Management: What About HDL?" American Association of Physician Assistants 34<sup>th</sup> Annual Meeting, San Francisco, California, May 28, 2006.
197. "Hyperlipidemia", Georgia Society of Health-System Pharmacists Summer Meeting, Amelia Island, Florida, July 8, 2006.
198. "Cholesterol Control in Patients with Hypertension and Multiple Risk Factors", American Society of Health-System Pharmacists Midyear Clinical Meeting, Anaheim, California, December 3, 2006.
199. "Transforming the Minds of Students by Infusing Critical Thinking into the Curriculum", The 27th International Conference on Critical Thinking, Berkley, California, July 25, 2007.
200. "Designing a Team-Based Learning Curriculum in Health Professions Education", Faculty Development Workshop, Regis University, Denver, CO, January 23, 2009.
201. "Navigating the Critical Thinking Labyrinth", Institute on Developing Critical Thinkers, University of Louisville, Louisville, KY, May 29, 2009
202. "Transforming the Minds of My Students", Institute on Developing Critical Thinkers, University of Louisville, Louisville, KY, May 29, 2009
203. "Incorporating the History of Pharmacy into the Curriculum", American Association of Colleges of Pharmacy, Boston, MA, July 20, 2009.
204. "Transforming Pharmacy Education through Team-Based Learning", American Association of Colleges of Pharmacy, Boston, MA, July 21, 2009.
205. "How to Design a Team-based Learning Course in Pharmacy", Faculty Development Workshop, University of the Incarnate Word School of Pharmacy, San Antonio, TX, June 23, 2010.
206. "Developing the Questioning Mind Through Team-Based Learning", 30th International Conference on Critical Thinking, Berkeley, CA, July 22, 2010.
207. "Continuous Formative Assessment of Team-Based Learning: RATs, BATs, and CATs", Team-Based Learning Collaborative Annual Meeting, Las Vegas, NV, March 6, 2011.
208. "Assessment of Student Learning Using Electronic Platforms", Western Association of Schools and Colleges Academic Resource Conference, San Francisco, CA, April 7, 2011.
209. "Transforming Students in the Classroom: From Death by PowerPoint to Cooperative Team-based Learning" (with Lane Brunner, PhD), Western Association of Schools and Colleges Academic Resource

Conference, San Francisco, CA, April 7, 2011.

210. "Getting Faculty Involved in Assessing and Improving Students' Critical Thinking" (with Michael Grant, PhD, Ada Haynes, PhD, and Barry Stein, PhD), Western Association of Schools and Colleges Academic Resource Conference, San Francisco, CA, April 8, 2011.
211. "How to Improve the Team-Based Learning Pedagogy", Faculty Development Workshop, University of Michigan College of Pharmacy, Ann Arbor, MI, October 20, 2011.
212. "Professionalism", White Coat Ceremony Keynote Presentation, University of Michigan College of Pharmacy, Ann Arbor, MI, October 20, 2011.
213. "Developing Skills for the 21st Century: Assessing and Improving Critical Thinking", (with Barry Stein, PhD and Ada Haynes, PhD, Western Association of Schools and Colleges Academic Resource Conference, Costa Mesa, CA, April 19, 2012.

#### **NATIONAL SYMPOSIA CHAIR/MODERATOR:**

"The Pathophysiology and Treatment Interactions Between Hypertension and Atherosclerosis". American College of Clinical Pharmacy Annual Meeting, Toronto, Ontario, Canada, August 8, 1992.

"Dyslipidemia and Coronary Disease: Emerging Issues in Secondary Prevention", American College of Clinical Pharmacy Annual Meeting, Reno, Nevada, August 15, 1993.

"DVT Prophylaxis: An Outlook on Cost-Effectiveness", American Society of Hospital Pharmacists Midyear Clinical Meeting, Atlanta, Georgia, December 5, 1993.

"Advances in the Treatment of Deep Vein Thrombosis: A Focus on Low Molecular Weight Heparin," American Society of Hospital Pharmacists Midyear Clinical Meeting, Miami, Florida, December 4, 1994.

"Emerging Concepts in the Clinical Use of Low Molecular Weight Heparins," American Society of Health-System Pharmacists Annual Meeting, Philadelphia, Pennsylvania, June 4, 1995.

"New Approaches in the Treatment of Thrombotic Disorders," American College of Clinical Pharmacy Annual Meeting, Washington, DC, August 8, 1995.

"Low Molecular Weight Heparins: A Decade of Basic and Clinical Developments," International Society of Haematology (European and African XIII Meeting, Istanbul, Turkey, September 7, 1995.

"Advances in Antithrombotic Therapy," American Society of Health-System Pharmacists Midyear Clinical Meeting, Las Vegas, Nevada, December 5, 1995.

"Expanding Therapeutic Horizons: Arterial Indications for Low Molecular Weight Heparins," American College of Clinical Pharmacy Annual Meeting, Phoenix, Arizona, November 9, 1997.

"New Dynamics of Cholesterol Lowering: Success at an Affordable Cost," American Society of Health-System Pharmacists Annual Meeting, Baltimore, Maryland, June 1, 1998.

"Improving the Quality of Cardiovascular Care: A Mandate for the New Millennium", Association of Managed Care Pharmacists National Meeting, Atlanta, Georgia, October 6, 1999.

"Venous Thromboembolism: Modulating the Coagulation Cascade", American Society Health-System Pharmacists Midyear Clinical Meeting, Las Vegas, Nevada, December 5, 2000.

"DVT: Clinical and Economic Implications of Alternate Site Treatment", American Pharmaceutical Association 148<sup>th</sup> Annual Meeting, San Francisco, California, March 19, 2001.



“Simplifying Anticoagulation: Clinical Updates in the Prevention and Treatment of Thromboembolism”, American College of Clinical Pharmacy Annual Meeting, Tampa, Florida, October 23, 2001.

“Aggressive Control of Type 2 Diabetes: How Pharmacy Will Play a Greater Role”, American Society of Health-System Pharmacists Midyear Clinical Meeting, New Orleans, Louisiana, December 3, 2001.

“Optimizing Control of Type 2 Diabetes: The Pharmacists’ Role”, American Pharmaceutical Association Annual Meeting, Philadelphia, Pennsylvania, March 17, 2002.

“Hypertension in Jeopardy”, Academy of Managed Care Pharmacy Annual Meeting, Salt Lake City, Utah, April 3, 2002.

“Evolution in the Management of Thrombotic Disorders: The Role of Factor Xa Inhibition in the Continuum of Care”, American Society of Health-System Pharmacists Midyear Clinical Meeting, Atlanta, Georgia, December 8, 2002.

“New Approaches to Oral Anticoagulation: The Evolving Role of Pharmacists”, American Society of Health-System Pharmacists Midyear Clinical Meeting, Atlanta, Georgia, December 9, 2002.

“Practical Guidelines for Setting Up Lipid Lowering Clinics”, American College of Clinical Pharmacy Annual Meeting, Atlanta, Georgia, November 2, 2003.

“Pharmacy Invitational Conference on Antithrombotic Therapy (PICAT, 20<sup>th</sup> Anniversary Meeting), Las Vegas, Nevada, December 3, 2005.

#### **PUBLICATIONS:**

1. Ebel JA, Wilson D, Hawkins DW: Preparation, Storage and Use of Skin Bank Fluid in a Community Hospital, *Voices* 12:60, Vol. 3, No. 3, 1973.
2. Hawkins DW: Serum Transaminases, *Hospital Pharmacy*, 9:155, 1974.
3. Kelch R, Clemens L, Markous M, Westoff M, Hawkins DW: Metabolism and Effects of Synthetic Gonadotropic Releasing Hormone (GNRH) in Children and Adults, *J. Clin. End. Metab*; 40:53, 1975.
4. Ludden TM, Hawkins DW, Allen JP, Hoffman SF: Optimum Phenytoin Dosage Regimens, *Lancet* 1:307, 1976. (Letter)
5. Hawkins DW, Ludden TM, Allen JP, Hoffman SF: Hypermetabolism of Phenytoin: A Pharmacokinetic Study, *Neurology* 26:343, 1976. (Abstract)
6. Hawkins DW: "Doctor and Drug-Induced Diseases," (Chapter 22), In Problem-Solving in Clinical Medicine, Paul Cutler, ed., Williams and Wilkins, Baltimore, 1979, pp. 344-348.
7. Hawkins DW, Ludden TM, Hoffman SF, and Allen JP. Rapid Metabolism of Phenytoin: A Method to Calculate Proper Dosage, *Arch Neurology*, 36:109-110, 1979.
8. Hawkins DW: "Family Practice and the Pharmacist," In Selected Topics in Drug Therapy II, Symposia Specialists, Inc., Miami, 1978, pp. 3-11.
9. Hawkins DW: Angina - Pathophysiology and Treatment, *The Continuing Education Guide for Pharmacists*, 4:9-18, 1979.
10. Hawkins DW, Fiedler FP, Douglas HL, and Eschbach RE: Evaluation of a Clinical Pharmacist in Caring

for Hypertensive and Diabetic Patients, Am. J. Hosp. Pharm. 36:1321-1325, 1979.

11. Hawkins DW: Clinical Pharmacy Functions in Ambulatory Patient Care, J. Clin. Pharmacology 21:245-250, 1981.
12. Hawkins DW: "Organization and Patient Care Functions of the Anticoagulation Clinic," In Grand Rounds in Medicine: Recognition and Management of Thromboembolic Disorders, pp. 63-68, Professional Postgraduate Services, Inc., 1982.
13. Hawkins DW: "The Need for Anticoagulation Clinics," In The Triad of Successful Anticoagulation Management: Pharmacist, Clinician and Patient, KPR Infor Media Corp, New York, 1983.
14. Hawkins DW: "Anticoagulation Clinic Care Compared with Routine Care: A Proposed Multi-Center Study," in The Triad of Successful Anticoagulation Management: Pharmacist, Clinician and Patient, KPR Infor Media Corp, New York, 1983.
15. Hendrickson WD, Hawkins DW, Littlefield JH, et al: Effects of Providing Feedback Lecture via Videotape Recordings and Observer Critiques, Am J Pharm Ed, 47:239-244, 1983.
16. Mungall DR, Wong YY, Talbert R, Marshall S, Hawkins DW, et al: Comparison of Plasma Protein Binding between Ultrafiltration and Equilibrium Dialysis, Clin Pharm Ther, 33:258, 1983. (Abstract)
17. Mungall D, Ludden T, Marshall J, Crawford M, and Hawkins D: Relationships between steady-state Warfarin Concentrations and Anticoagulant Effect, Clin Pharmacokinetics, 9(Suppl 1): 99-100, 1984.
18. Family Physicians Hypertension Study Group: A Multicomparison of the Antihypertensive Effects of Atenolol and Chlorthalidone Given Alone and in Combination, Curr Therp Res 35:31-39, 1984.
19. Mungall DR, Ludden TM, Hawkins DW et al: Effect of Diltiazem on Warfarin Plasma Protein Binding, J Clin Pharmacol 24:246-266, 1984.
20. Evens RP and Hawkins DW: Bone and Joint Disorders in Current Geriatric Therapy, Covington TR and Walker JI (eds), WB Saunders Company, Philadelphia, 1984.
21. Bussey HI, Hawkins DW, and Gaspard JJ: Digoxin vs. Digitoxin in the Treatment of Congestive Heart Failure, Drug Intell Clin Pharm 19:458, 1985. (Abstract)
22. Hawkins DW: Doctor-and-Drug-induced Diseases in Problem Solving in Clinical Medicine, 2nd ed, Paul Cutler (ed), Williams and Wilkins, Baltimore, 1985.
23. Hawkins DW, Tabor PA, Kruse JM et al: Appropriateness and Effectiveness of Clinical Pharmacy Recommendations, Fam Pract Res J 5(1): 36-42, 1985.
24. Mungall DR, Ludden TM, Marshall J, Hawkins DW et al: Population Pharmacokinetics of Racemic Warfarin in Adult Patients, J Pharmacokin Biopharm 13(3): 213-227, 1985.
25. Bussey HI, Watson WA, and Hawkins DW: Practical Value of a New Serum Digitoxin Assay, Ther Drug Monit 8:90-94, 1986.
26. Hawkins DW: Depression in the Elderly, The Network for Continuing Medical Education, No 478, pp 8-15, 1986.
27. Hawkins DW: Management of the Ambulatory Gout Patient, Wellcome Trends in Pharmacy 9:6-12, 1987.
28. Hawkins DW: Unit Introduction: Drugs to Treat Endocrine System Disorders In Clinical Pharmacology and Nursing, CL Baer and BR Williams (eds), Springhouse Publishing Company, Springhouse,

Pennsylvania, 1988.

29. Hawkins DW, Dieckmann MR, Horner R: Diuretics and Hypertension in Black Adults, *Arch Inter Med* 146:803-805, 1988.
30. Bussey HI and Hawkins DW: Pseudopheochromocytoma and Multiple Antihypertensives, *Hospital Therapy* 13:61-67, 1988.
31. Hawkins DW: Gout and Hyperuricemia In Pharmacotherapy: A Pathophysiologic Approach, JT DiPiro, P Hayes, LM Posey, R Talbert, G Yee (eds), Elsevier Science Publishing Company, New York, New York, 1989.
32. Hawkins DW and Bussey HI: Hypertension In Pharmacotherapy: A Pathophysiologic Approach, JT DiPiro, P Hayes, LM Posey, R Talbert, G Yee (eds), Elsevier Science Publishing Company, New York, New York, 1989.
33. Bussey HI, Hawkins DW, Gaspard JJ, and Walsh RA: A Comparative Trial of Digoxin and Digitoxin in the Treatment of Congestive Heart Failure, Pharmacotherapy 1988; 8:235-240.
34. Hawkins DW: Drugs to Treat Endocrine Disorders: Unit Introduction in Essentials of Clinical Pharmacology in Nursing, R Williams and CL Baer (eds), Springhouse Corporation, Springhouse, Pennsylvania, 1992.
35. Hawkins DW, Bussey HI, Prisant LM: Hypertension in Pharmacotherapy: A Pathophysiologic Approach, JT DiPiro, R Talbert, P Hayes, G Yee, G Matzke, LM Posey (eds), 2nd Edition, Elsevier Science Publishing Company, New York, 1992.
36. Hawkins DW: Gout and Hyperuricemia in Pharmacotherapy: A Pathophysiologic Approach, JT DiPiro, R Talbert, P Hayes, G Yee, G Matzke, LM Posey (eds), 2nd Edition, Elsevier Science Publishing Company, New York, 1992.
37. Bussey HI and Hawkins DW: Pharmacotherapy Self Assessment Program on Hypertension, American College of Clinical Pharmacy, 1992.
38. Prisant LM, Carr AA, Hawkins DW: Treating Hypertensive Emergencies, *Postgraduate Medicine*, 1993;93:92-110.
39. Hawkins DW: Who Decides the Future of Pharmacy Education and Practice (Commentary), *Pharmacotherapy* 1993; 13:162-164.
40. Hawkins DW: DVT Prophylaxis Following Hip Replacement Surgery: A Focus on Enoxaparin. *Hospital Pharmacist Report Supplement*, 1993.
41. Hawkins DW and Gilliard FE: Comparative Pharmacology of Antithrombotic Agents. *Hospital Pharmacist Report Supplement*, 1994.
42. Hawkins DW and Gilliard FE: Guidelines for the Prevention and Treatment of Deep Vein Thrombosis. *Hospital Pharmacist Report Supplement*, 1994.
43. Hawkins DW and Gilliard FE: The Safety and Efficacy of Low Molecular Weight Heparins in the Prevention and Treatment of Deep Vein Thrombosis. *Hospital Pharmacist Report Supplement*, 1994.
44. Hawkins DW, Hall WD, Douglas MB, Cotsonis G. A Multi-Center Analysis of the Use of Enalapril and Lisinopril in Elderly Hypertensive Patients. *J Am Ger Soc* 1994; 42:1273-1276.
45. McKenney JM, Hawkins DW (editors). Handbook on the Management of Lipid Disorders. Scientific Therapeutics Information, Inc., Springfield, New Jersey, 1995.

46. Hawkins DW. The Pharmacology of Low Molecular Weight Heparins. *Thrombosis Forum* 1995; 1:5-8.
47. Hawkins DW. Advances in the Management of Deep Vein Thrombosis: A Focus on Low Molecular Weight Heparins. *Pharmacy and Therapeutics* 1995; 20(6S): 1S-31S.
48. Hawkins DW. Drugs to Treat Endocrine System Disorders: Unit Introduction In Clinical Pharmacology and Nursing, third edition, CL Baer and BR Williams (eds), Springhouse Corporation, Springhouse, PA, 1996.
49. Hawkins DW. Global economic perspective on the use of low molecular weight heparin. *Clin Appl Thrombosis/Hemostasis* 1996; 2(suppl 1): S40-43.
50. Wade WE, Spruill WJ, Taylor AT, Longe RL, and Hawkins DW. The expanding role of pharmacy and therapeutics committees: the 1990s and beyond. *Pharmacoeconomics* 1996; 10:123-128.
51. Chisholm MA, Hawkins DW, Taylor AT, Curtis P. An analysis of pharmaceutical care provided by doctor of pharmacy clerkship students in an acute care setting: are pharmacy students beneficial to patient care? *International Pharmaceutical Abstracts* 1996; 33:2340.
52. Hawkins DW, Bussey HI, Prisant LM. Hypertension in Pharmacotherapy: A Pathophysiologic Approach, JT DiPiro, RL Talbert, GC Yee, GR Matzke, BG Wells, LM Posey (eds), 3rd Edition, Appleton & Lange, Stamford, CT, 1997.
53. Hawkins DW, Rahn DW. Gout and hyperuricemia in Pharmacotherapy: A Pathophysiologic Approach, JT DiPiro, RL Talbert, GC Yee, GR Matzke, BG Wells, LM Posey (eds), 3rd Edition, Appleton & Lange, Stamford, CT, 1997.
54. Chisholm MA, Hawkins DW, Taylor AT. Providing pharmaceutical care: are pharmacy students beneficial to patient care? *Hospital Pharmacy* 1997; 32:370-375.
55. Chisholm MA, Hawkins DW. Analysis of pharmacotherapy recommendations provided by doctor of pharmacy clerkship students. *J Pharmacy Teaching* 1996; 5:3-12
56. Hawkins DW. Drug interactions with lipid lowering agents. *Cardiology Special Edition* 1997; 3:71-73.
57. Hawkins DW, Langley PC, Krueger KP. Pharmacoeconomic model of enoxaparin versus heparin for prevention of deep vein thrombosis after total hip replacement. *Am J Health-Syst Pharm* 1997; 54:1185-1190.
58. Hawkins DW, Hirsh J. Antithrombotic drugs for thromboembolic disorders: a lesson in evidence-based medicine. *Am J Health-Syst Pharm* 1997; 54:1992-1994.
59. Chisholm MA, Taylor AT, and Hawkins DW. Pharmaceutical care provided by doctor of pharmacy clerkship students in geriatric patients in an acute care setting. *J Ger Drug Ther* 1997; 11:43-50.
60. Hawkins DW, Langley PC, Krueger KP. A pharmacoeconomic assessment of enoxaparin and warfarin as prophylaxis for deep vein thrombosis in patients undergoing knee replacement surgery. *Clin Ther* 1998; 20:182-195.
61. Hawkins DW. Drugs to treat endocrine system disorders in Essentials of Clinical Pharmacology in Nursing, Third Edition, Springhouse Corporation, Springhouse, PA, 1998.
62. Hawkins DW, Bussey HI, Prisant LM. Hypertension in Pharmacotherapy: A Pathophysiologic Approach, JT DiPiro, RL Talbert, GC Yee, GR Matzke, BG Wells, LM Posey (eds), 4th Edition, Appleton & Lange, Stamford, CT, 1999: 131-152.

63. Hawkins DW, Rahn DW. Gout and hyperuricemia in Pharmacotherapy: A Pathophysiologic Approach, JT DiPiro, RL Talbert, GC Yee, GR Matzke, BG Wells, LM Posey (eds), 4th Edition, Appleton & Lange, Stamford, CT, 1999: 1460-1465.
64. Hawkins DW. Misadventures in drug metabolism. The Lipid Nurse Task Force Bulletin 1999; 5:1-2, 10.
65. Cushner FD, Cannavo D, Freidman RJ, Hawkins DW, et al. Safe and effective use of low-molecular weight heparin to prevent DVT in orthopedic patients. (Monograph) Sci-Health Communications, Cincinnati, Ohio, 1999.
66. Stratton MA, Anderson FA, Hawkins DW, et al. Prevention of venous thromboembolism: adherence to the 1995 American College of Chest Physicians Consensus Guidelines for Surgical Patients. Arch Intern Med 2000; 160: 334-340.
67. Tate N, Reed P, Hawkins D, et al. ACE inhibitors and their utilization in managed care. Am J Manag Care 2000; 6 (suppl): S132-140.
68. Wade WE, Hawkins DW. Cost effectiveness of outpatient anticoagulation prophylaxis after total hip arthroplasty. Orthopedics 2000; 23: 335-339.
69. Hawkins David, Jackson Jay. Application of pharmacoeconomics in cardiovascular disease: economic evaluation of lipid-lowering therapies in Introduction to Applied Pharmacoeconomics, F. Randy Vogenberg (ed), McGraw-Hill, New York, 2001.
70. Hawkins David. Drug Interactions with Lipid-Lowering Agents 2001, McMahon Publishing Group, New York, 2001.
71. Hawkins D, McKenney JM, Covey DF, Hutchinson LC. Therapeutic lifestyle changes. In: McKenney JM and Hawkins D, eds. Handbook on the Management of Lipid Disorders, 2<sup>nd</sup> edition. Springfield, NJ: Scientific Therapeutics Information, 2001: 94-123.
72. Sisson EM, Weart CW, Hawkins D, Rider S. Diabetes. In: McKenney JM and Hawkins D, eds. Handbook on the Management of Lipid Disorders, 2<sup>nd</sup> edition. Springfield, NJ: Scientific Therapeutics Information, 2001:215-225
73. Hawkins D, Cziraky MJ, Willey VJ. Hypertension. In: McKenney JM and Hawkins D, eds. Handbook on the Management of Lipid Disorders, 2<sup>nd</sup> edition. Springfield, NJ: Scientific Therapeutics Information, 2001:226-235.
74. Hawkins D. The metabolic syndrome. In: McKenney JM and Hawkins D, eds. Handbook on the Management of Lipid Disorders, 2<sup>nd</sup> edition. Springfield, NJ: Scientific Therapeutics Information, 2001:236-241.
75. Hawkins D. Drug interactions with lipid-lowering agents. Prim Care Special Edition 2001; 5: 19-24.
76. Hawkins DW. Recent advances in the prophylaxis of venous thromboembolism: modulating the coagulation cascade: Introduction. Am J Health-Syst Pharm 2001; 58 (suppl 2): S2-3.
77. Hawkins D. Dosing, dosage forms, and pharmacokinetics of low-molecular-weight heparins. In: McGill KA, ed. 2001 Update on Anticoagulation Therapy. Madison: Extension Services in Pharmacy, University of Wisconsin, 2001: 117-123.
78. Hawkins D. Drug interactions with lipid-lowering agents. Cardiology Special Edition 2001; 7: 35-38.
79. Hawkins D, Bradberry JC, Cziraky MJ, et al. National Pharmacy Cardiovascular Council treatment guidelines for the management of type 2 diabetes mellitus: toward better patient outcomes and new roles

for pharmacists. *Pharmacotherapy* 2002; 22: 436-444.

80. Hawkins DW, Rahn DW. Gout and hyperuricemia in Pharmacotherapy: A Pathophysiologic Approach, JT DiPiro, RL Talbert, GC Yee, GR Matzke, BG Wells, LM Posey (eds), 5th Edition, McGraw-Hill, New York, 2002: 1659-1664.
81. Bauer KA, Hawkins DW, Peters PC, et al. Fondaparinux, a synthetic Pentasaccharide: the first in a new class of antithrombotic agents – the selective factor Xa inhibitors. *Cardiovascular Drug Reviews* 2002; 20: 37-52.
82. Hawkins DW. Drug interactions with lipid-lowering agents. *Cardiology Special Edition* 2002; 8: 51-54.
83. Hawkins DW. Aggressive management of dyslipidemia. *Clinical Trends* 2002; 2: 24-33. (Located at [www.fujisawa.com/medinfo/cont\\_educ/clin\\_trnd\\_main.htm](http://www.fujisawa.com/medinfo/cont_educ/clin_trnd_main.htm))
84. Hawkins D. Speaking for hire. *Am J Health-Syst Pharm* 2002; 59:1870-1871. (Commentary)
85. Hawkins, DW, Bauer KA, Eriksson BI, et al. Consistency of fondaparinux superiority for venous thromboembolism prevention in orthopedic surgery according to different composite efficacy endpoints. *Pharmacotherapy* 2002; 22: 1344-1345. (Abstract)
86. Hawkins D. Charles Walton in Encyclopedia of Clinical Pharmacy, JT DiPiro (ed), Marcel Dekker, Inc, New York, 2003: 899-901.
87. Cannon CP, Hawkins D, Hixson-Wallace J. A primary physician's guide to cardiovascular agents. *Primary Care Special Edition* 2003; 7: 15-23.
88. Hixson-Wallace J, Hawkins D, Cannon, CP. Guide to cardiovascular agents. *Cardiology Special Edition* 2003; 9:27-37.
89. Hawkins D. Clinical trials with factor Xa inhibition in the prevention of postoperative venous thromboembolism. *Am J Health-Syst Pharm* 2003; 60(Suppl 7): S6-S10.
90. Hawkins D. Evolution in the management of thrombotic disorders: the role of factor Xa inhibition in the continuum of care: Introduction. *Am J Health-Syst Pharm* 2003; 60(Suppl 7): 52.
91. Cannon CP, Hawkins D, Hixson-Wallace J. Guide to antithrombotic agents. *Cardiology Special Edition* 2004; 10:57-62.
92. Munger MA, Hawkins DW. Atherothrombosis: epidemiology, pathophysiology, and prevention. *JAPhA* 2004; 44 (suppl 1): S5-S13.
93. Hawkins DW. Limitations of traditional anticoagulants. *Pharmacotherapy* 2004; 24 (7 Pt 2):62S-65S.
94. Hawkins DW. Pharmacoeconomics of thrombosis management. *Pharmacotherapy* 2004; 24 (7 Pt 2):95S-99S.
95. Hawkins D. The role of oral direct thrombin inhibitors in the prophylaxis of venous thromboembolism. *Pharmacotherapy* 2004; 24 (10 Pt 2):179S-183S.
96. Hawkins D. Economic considerations in the prevention and treatment of venous thromboembolism. *Am J Health-Syst Pharm* 2004; 61 (Suppl 7): S18-21.
97. Hawkins D. Anticoagulation: The role of economics in pharmacologic decision making. *Anticoagulation Digest* 2004; 1(5):1-6.
98. Hawkins D, Evans J. Minimizing the risk of heparin-induced osteoporosis during pregnancy. *Expert*

Opin Drug Safety 2005; 4:583-590.

99. Cannon C, Hawkins D, McKeever A. Antithrombotic agents.: Guide to cardiovascular agents. Cardiology Special Edition 2005; 11:39-49.
100. Gotto A, Hawkins D, McKeever A. Challenges in cardiovascular risk reduction. Cardiology Special Edition 2005; 11:59-64.
101. Hawkins DW and Rahn DW. Gout and hyperuricemia in Pharmacotherapy: A Pathophysiologic Approach, JT DiPiro, RL Talbert, GC Yee, GR Matzke, BG Wells, LM Posey (eds), 6th Edition, McGraw-Hill, New York, 2005: 1705-1711.
102. Hawkins D and Huston S. Pharmacoeconomic considerations in anticoagulant drug use. Expert Opin Pharmacotherapy 2006; 7:989-1003.
103. Schweiger T and Hawkins D. Long-term care of the post-MI patient. Drug Topics, June 19, 2006.
104. Nutescu EA, Wittkowsky AK, Dobesh PP, Hawkins DW, and Dager WE. Choosing the appropriate antithrombotic agent for the prevention and treatment of VTE: A case-based approach. Ann Pharmacotherapy 2006; 40:1558-1571.
105. Cannon C, Hawkins D, McKeever A. Guide to cardiovascular agents. Cardiology Quarterly 2007; 13:49-70.
106. Huston S and Hawkins D. Pharmacoeconomics of anticoagulants in acute coronary syndrome and percutaneous coronary intervention Current Pharmaceutical Design 2008; 14:1197-1204.106.
107. Hawkins D, Elder L, Paul R. The Thinkers Guide to Clinical Reasoning, Foundation for Critical Thinking, 2010.
108. Feng X, Ofstad W, Hawkins D. Antiangiogenesis Therapy: a new strategy for cancer treatment. US Pharm 2010; 35(Oncology suppl): 4-9.
109. Hawkins D (editor) A Team-Based Learning Guide for Faculty in the Health Professions. Author House, LLC. 2014.
110. Hawkins D. A Team-Based Learning Guide for Students in Health Professional Schools. Author House, LLC. 2014
111. Hawkins D. A Team-Based Learning Guide for Faculty. Stratton Press, 2020.

#### **OTHER CREATIVE WORKS: Educational Films, etc.**

"Helping Yourself . . . The Control of Blood Clotting," Endo Laboratories, Inc., Wilmington, Delaware 1982.

"The Key to Control: Insights Into Controlled Drug Delivery", Medi Cine, Inc., New York, New York, 1993.

"DVT Prophylaxis: An Outlook on Cost-Effectiveness", Excerpta Medica, 1993 (with Jack Hirsh, MD, Guy Paiement, MD and Sean Sullivan, PhD).

"Advances in the Management of Deep Vein Thrombosis: A Focus on Low Molecular Weight Heparins", Gardiner-Caldwell Synermed, 1996 (with Alexander Turpie, MD, Jawed Fareed, PhD, David Anderson, MD and Mary O'Connell, PharmD).

“Current Concepts in Hypertension”, Medivision, 1998 (with Wayne Weart, PharmD and Nancy Miller, RN).

“Prophylaxis and Treatment of Thromboembolic Disorders”, Virginia Commonwealth University, 1998.

“Topics in Medicine: Differentiation of Low Molecular weight Heparins: Clinical and Economic Implications of Treatment”, Interactive Medical Networks, 1999 (with Christopher Cannon, MD, Joseph Caprini, MD, and Geno Merli, MD).

“Hypertension: getting to goal”, Drug Store News Continuing Education Quarterly, April-June 2002: 21-28 (with Julie Hixson-Wallace, PharmD).

Hawkins D and Wilkinson JJ. Hyperlipidemia: The Importance of Treating to Goal. Drug Topics On-line Continuing Education Program, July, 2006.

“Acute Coronary Syndrome: Peer Points: The Pharmacist’s Perspective”, CD-ROM for continuing medical education, Postgraduate Institute for Medicine, January 29, 2007.

#### **RESEARCH GRANTS AND CONTRACTS:**

Title: A Primary Care Clinical Laboratory for Pharmacy Research and Training.  
Source: Robert Wood Johnson Foundation  
Amount: \$539,400.00  
Status: Not funded

Title: A Primary Care Clinical Laboratory for Pharmacy Research and Training.  
Source: Department of Health, Education and Welfare Health Professions Special Project  
Amount: \$240,981.00  
Status: Completed

Title: A Multiclinic Controlled Study to Evaluate the Antihypertensive and Potassium Conserving Effects of Amiloride and Moduretic Compared to Hydrochlorothiazide in Patients with Mild to Moderate Uncomplicated Essential Hypertension.  
Source: Merck, Sharp and Dohme Research Laboratories  
Amount: \$51,370.00  
With: Herschel L. Douglas, M.D., Department of Family Practice, The University of Texas Health Science Center at San Antonio  
Status: Completed

Title: Evaluating Clinical Pharmacy Practice in a Rural Community.  
Source: Department of Health, Education, and Welfare  
Amount: \$39,624.00  
Status: Approved, but not funded.

Title: A Prospective Clinical Trial to Evaluate the Antihypertensive Effectiveness and Incidence of Reflex Tachycardia of Prazosin When Used in Combination with a Diuretic Only in the Treatment of Essential Hypertension.  
Source: Pfizer Research Laboratories  
Amount: \$2,000.00  
Status: Completed



Title: Evaluation of Quinine in the Prevention and Treatment of Nocturnal Recumbency Leg Cramps.  
 Source: Merrell Research Center  
 Amount: \$5,800.00  
 With: Herschel L. Douglas, M.D., Department of Family Practice, The University of Texas Health Science Center at San Antonio  
 Status: Completed

Title: Improving the Precision of Anticoagulant Drug Therapy.  
 Source: National Center for Health Services Research  
 Amount: \$34,829.00  
 Status: Not Funded

Title: Evaluation of the Antihypertensive Effect of Aldoril Once Daily Compared to Aldoril Twice Daily.  
 Source: Merck, Sharp and Dohme Research Laboratories  
 Amount: \$24,170.00  
 With: Don B. Cauthen, M.D., Department of Family Practice, The University of Texas Health Science Center at San Antonio  
 Status: Funded but terminated by investigators

Title: A Multi-Center Comparison of the Antihypertensive Effects of Atenolol and Chlorthalidone Given Alone and in Combination.  
 Source: I.C.I. Americas, Inc.  
 Amount: \$30,824.00  
 With: Shelley P. Roaten, Jr., M.D., Department of Family Practice, The University of Texas Health Science Center at San Antonio  
 Status: Completed

Title: Decentralized Inpatient and Outpatient Pharmacy Study.  
 Source: Health Care Studies Division, U.S. Army  
 Amount: \$498,786.00  
 With: Larry Ereshefsky, Pharm.D. (Co-Principal Investigator)  
 Status: Not Funded

Title: A Serum Concentration Comparison of Digoxin and Digitoxin.  
 Source: University Research Institute, The University of Texas at Austin  
 Amount: 5,000.00  
 With: Henry I. Bussey, Pharm.D. (Principal Investigator)  
 Status: Completed

Title: Tegretol vs. Phenytoin in Epileptic Children Under Six Years of Age.  
 Source: Ciba-Geigy Corporation  
 Amount: \$70,000.00  
 With: G. Earl Trevathan, M.D. (Principal Investigator)  
 Status: Completed

Title: High Dose Diuretic versus Usual Dose Diuretic plus Beta Blocker in the Treatment of Hypertension in Black Adults.  
 Source: Ciba-Geigy Corporation

Amount: \$119,926.00  
Status: Completed

Title: Developing and Evaluating a Network of Regional Drug Therapy Consultation Centers for Improving the Precision and Safety of Pharmacotherapy in the Older Population.  
Source: John A. Hartford Foundation, Inc.  
Amount: 499,806.00  
Status: Not Funded

Title: A Randomized Crossover Trial of USP-DI and AHFS-DI in Finding Answers to Drug Therapy Questions Generated by Patient Care.  
Source: The United States Pharmacopeial Convention, Inc.  
Amount: \$4,500.00  
Status: Completed

Title: A Randomized Double-Blind Clinical Equivalency Trial of Cimetidine Vs. Diphenhydramine in the Treatment of Acute Urticaria  
Source: Smith Kline & French Laboratories  
Amount: \$62,500.00  
Status: Not Funded

Title: Evaluation of Physicians', Physician Assistants', and Medical Students' Drug Information Resources  
Source: The Upjohn Company  
Amount: 750.00  
Status: Completed

Title: Efficacy and Safety of Enoxaparin versus Heparin for Prevention of Deep Vein Thrombosis after Hip Replacement  
Source : Rhone-Poulenc Pharmaceuticals  
Mount : \$100,620.00  
With: Joseph DiPiro, Pharm.D. (Principal Investigator)  
Status: Completed

Title: A multicenter, randomized, parallel, double-blind, dose-ranging study of subcutaneous SR 90107A/ORG 31540 with an assessor blind, comparative control group of subcutaneous LMWH in the prevention of deep vein thrombosis after elective total hip replacement.  
Source: Sanofi Research Division  
Amount: \$120,000  
Status: Completed

#### **SPECIAL HONORS/AWARDS:**

The Rho Chi Society

Faculty Research Assignment Award, University of Texas at Austin University Research Institute, September 1, 1982 - December 31, 1982

President, Ahlquist Chapter of American College of Clinical Pharmacology

President, Southeast Chapter of American College of Clinical Pharmacology

Robert G. Leonard Memorial Lecturer, 1995-96, The University of Texas at Austin and the Texas Society of Health-System Pharmacists

Georgia Pharmacists Magazine Dedication (1996)

The Pharmacy Practice Research Award of the ASHP Research and Education Foundation (1998)

**SCIENTIFIC AND PROFESSIONAL SOCIETIES:**

American College of Clinical Pharmacy (Fellow)

American College of Clinical Pharmacology (Fellow)

The International Academy of Clinical and Applied Thrombosis and Hemostasis (Fellow)

American Heart Association for High Blood Pressure Research (Fellow)

American Association of Colleges of Pharmacy

National Pharmacy Cardiovascular Council